Abstract:Immunotherapy with checkpoint blockade induces rapid and durable immune control of cancer in some patients and has driven a monumental shift in cancer treatment. Neoantigen-specific CD8+ T cells are at the forefront of current immunotherapy strategies, and the majority of drug discovery and clinical trials revolve around further harnessing these immune effectors. Yet the immune system contains a diverse range of antitumour effector cells, and these must function in a coordinated and synergistic manner to overcome the immune-evasion mechanisms used by tumours and achieve complete control with tumour eradication. A key antitumour effector is the natural killer (NK) cells, cytotoxic innate lymphocytes present at high frequency in the circulatory system and identified by their exquisite ability to spontaneously detect and lyse transformed or stressed cells. Emerging data show a role for intratumoural NK cells in driving immunotherapy response and, accordingly, there have been renewed efforts to further elucidate and target the pathways controlling NK cell antitumour function. In this Review, we discuss recent clinical evidence that NK cells are a key immune constituent in the protective antitumour immune response and highlight the major stages of the cancer–NK cell immunity cycle. We also perform a new analysis of publicly available transcriptomic data to provide an overview of the prognostic value of NK cell gene expression in 25 tumour types. Furthermore, we discuss how the role of NK cells evolves with tumour progression, presenting new opportunities to target NK cell function to enhance cancer immunotherapy response rates across a more diverse range of cancers. This Review discusses the key role that natural killer (NK) cells play in driving an antitumour immune response throughout the progression of cancer from its initial development to its metastatic spread and eventual treatment, defined herein as the cancer–NK cell immunity cycle.

In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors

NK cell receptors in anti-tumor and healthy tissue protection: Mechanisms and therapeutic advances

Natural killer cells in cancer biology and therapy

NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?

Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors

Exploiting NK Cell Surveillance Pathways for Cancer Therapy

Natural killer cell-mediated immune surveillance in cancer: Role of tumor microenvironment

Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects

Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches

The cancer–natural killer cell immunity cycle

NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies

Biological role of NK cells and immunotherapeutic approaches in breast cancer

Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization

Roles of natural killer cells in immunity to cancer, and applications to immunotherapy

Natural Killer Cells: Tumor Surveillance and Signaling

NK Cell Dysfunction and Checkpoint Immunotherapy

Shaping of NK Cell Responses by the Tumor Microenvironment

The role of the natural killer (NK) cell modulation in breast cancer incidence and progress

NK cell-based cancer immunotherapy: from basic biology to clinical application.

Natural killer cells in cancer immunotherapy